Treamid Therapeutics

Treamid Therapeutics is a private, preclinical-stage biotech developing small molecule drugs for fibrotic and inflammatory conditions. Its lead asset, T03, has completed a Phase 1a study and is positioned for idiopathic pulmonary fibrosis (IPF), with additional exploratory programs in liver and renal fibrosis. The company operates with a lean model, leveraging collaborations with academic institutions and CROs while maintaining an in-house research lab to drive its discovery efforts forward.

Proprietary small molecule discovery and development platform with an in-house in vitro lab for early-stage research and assay development. All compounds are novel chemical entities under global patent protection.

The fibrosis therapeutic space is highly competitive, with numerous large pharma and biotech companies pursuing diverse mechanisms. Treamid's early-stage position requires it to demonstrate differentiated efficacy. In COPD and autoimmune diseases, the competitive intensity is even greater, requiring a highly targeted approach for success.